Purpose: To test the therapeutic efficacy of azithromycin (AZM), a macrolide antibiotic for prolonging murine "high-risk" corneal allograft survival.
C orneal allotransplantation is the main treatment to rescue vision that is lost because of corneal scarring and opacification. 1 Penetrating keratoplasty (full-thickness corneal transplantation) is the oldest and most common form of human solid tissue transplantation. The success of penetrating keratoplasty is high, with 5-year survival rates as high as 90%. 2 This is due in part to the immune-privileged characteristics of the cornea. Routine corneal transplants, where the donor cornea is grafted into an avascular noninflamed eye, require only local immunosuppression, most commonly corticosteroids. In contrast, vascularized or high-risk corneal transplant prognosis is poor, with rejection rates approaching 70% even with maximal local and systemic immune suppression. Strikingly, these rejection rates are even higher than those seen with living donor kidney transplantation where 5-year survival rates are above 80%. 3 Management of highrisk corneal transplants has until recently represented a slowly evolving and controversial field in ophthalmology.
Most investigators define a "high-risk" corneal transplant recipient as one with a previously failed corneal graft or a cornea with vascularization in at least 2 of 4 quadrants. 4 Recent studies from multiple laboratories have shown that corneal neovascularization disrupts the immune privilege of naive corneas. [5] [6] [7] [8] [9] [10] A common model of high-risk corneal transplantation involves grafting to corneal beds that are vascularized by placement of a suture in the central cornea before transplantation. 11 In this model, corneal allograft rejection is an immunologic process that is mediated mainly by allospecific CD4 + T cells. [12] [13] [14] [15] [16] [17] Immunosuppressive agents such as glucocorticoids that are employed to combat graft rejection in high-risk corneal transplantation are associated with systemic immune suppression and with ocular complications such as glaucoma and cataract. Thus, it is desirable to identify drugs capable of inhibiting corneal allograft rejection without major side effects including systemic immune suppression and ocular complications.
The macrolide family of antibiotics possess antiinflammatory properties that are independent of their bactericidal or bacteria-static actions. Roxithromycin, clarithromycin, and azithromycin (AZM) are macrolide antibiotics with known antiinflammatory actions when administered systemically. 18 AZM has been shown to significantly increase interleukin (IL)-10 expression by T cells without inhibiting IL-2 production, whereas clarithromycin treatment inhibited IL-2 production without elevating IL-10. 19, 20 Given the central role of IL-2 in generation of adaptive immunity, clarithromycin would have systemic immunosuppressive effects, whereas AZM might inhibit inflammation with less of an effect on systemic immunity. [21] [22] [23] Additionally, an ophthalmic formulation of AZM is already approved by the Food and Drug Administration for the treatment of bacterial conjunctivitis (AzaSite, 1.5% AZM solution in DuraSite; Inspire Pharmaceuticals Inc, Durham, NC).
AzaSite has been shown to directly reduce inflammation in the cornea after a thermal cautery. Specifically, topical administration of AzaSite to injured corneas caused mild and short-term reductions in the size of the inflammatory infiltrate and resulted in a shift to an antiinflammatory cytokine profile. 24 It has also been demonstrated that oral or injected AZM treatment reduces the production of inflammatory cytokines and chemoattractants such as CXCL1 and CXCL8 that are important players in corneal inflammation. [25] [26] [27] Thus, we hypothesized that AZM treatment could increase graft survival by suppressing the local inflammation without systemic immune suppression.
To test this hypothesis, we compared the incidence of corneal allograft rejection on suture-induced high-risk graft beds of mice treated daily with topical, oral, or topical and oral AZM. We found that all AZM treatment regimes significantly reduced the incidence of allograft rejection without altering the systemic allospecific T-cell response. Moreover, even corneas that ultimately rejected exhibited a delayed onset of opacity when treated with topical AZM.
MATERIALS AND METHODS

Animals
C57BL/6 and BALB/c mice from Jackson Laboratories (Bar Harbor, ME) were housed in the Animal Resource Facility at the University of Pittsburgh Medical Center. The use of animals was in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research, and all procedures were approved by the University of Pittsburgh Institutional Animal Care and Use committee.
Induction of Corneal Vascularization: High-Risk Model
Corneal neovascularization was induced in graft recipients by placing 2 full-thickness 11-0 nylon sutures (Sharppoint; Vanguard, Houston, TX) in the central cornea of female BALB/c mice. Corneal allografts were placed 1 month later when 75% of the recipient corneal beds exhibited vascularization.
Orthotopic Corneal Transplantation
Allogeneic orthotopic corneal transplantations were performed as previously described. 6 Briefly, the central 2 mm of donor corneas from C57BL/6 mice was excised and secured in recipient high-risk graft beds of BALB/c mice with 8 interrupted 11-0 nylon sutures (Sharppoint). Grafts were evaluated twice a week by a masked scorer using slit-lamp biomicroscopy. Mice with flat anterior chambers, ulceration, or other complication associated with surgical failure were excluded from the experiments. Transplanted mice either received no treatment, or received topical AzaSite (1 drop per day on the transplanted cornea), oral AZM [0.25 mg in 10 mL of phosphate-buffered saline (PBS) administered by mouth every day], or both treatments beginning on the day of transplantation and continuing throughout the follow-up period.
Scoring of Allografts
Transplanted corneas were scored at least twice a week in masked fashion by 2 investigators with a high degree of consensus. Opacification was scored based on the following parameters: 0 = clear graft; 0.5 = small isolated imperfections or regions of translucence in the graft; 1 = minimal translucence or haziness extending over the entire graft with complete visualization of the iris and pupil; 1.5 = translucence or haziness extending over the entire graft and/or regional opacity in a minority of the graft; 2 = stromal opacity over the majority of the graft with visualization of the pupil margin and the iris structures; 2.5 = stromal opacity extending over the majority of the graft with only small regional translucence allowing very limited and strongly obscured visualization of the iris; 3 = complete stromal opacity with no visualization of the iris structures; 3.5 = complete stromal opacity associated with a swollen or misshapen eye; and 4 = destruction of the graft, a loss of graft integrity or graft perforation. Rejection was defined by a score of $3 on 2 consecutive readings (no mice were allowed to progress to a score of 4 in this study). [28] [29] [30] Neovascularization was also quantified but was not used as a basis of rejection. Each quadrant was given a score ranging from 1 to 4 where 1 = neovascularization present at the limbus; 2 = neovascularization to the graft-host interface but not invading the graft; 3 = neovascularization extending into the graft; and 4 = neovascularization extending into the central cornea. The 4 quadrants were added and a score ranging from 0 to 16 was given at each time point.
Immunohistochemical Analysis of Inflammatory Infiltration of Corneal Allografts
Complete corneas, including the graft and the recipient tissue were harvested from mice at 25 days posttransplantation. Four incisions were made in the graft bed so that the cornea could be effectively mounted on a slide for imaging. The corneas were washed in PBS plus 4% fetal bovine serum and fixed for 2 hours in BD Cytofix/Cytoperm. The corneas were then blocked with anti-Fc receptor and stained with antimouse CD45 phycoerythrin, antimouse CD90.2 APC, and DAPI. Confocal images were acquired on a Nikon (Tokyo, Japan) A-1 confocal microscope using a ·20 oil immersion objective (0.85NA) and were analyzed with MetaMorph 7.7 software (Molecular Devices, Sunnyvale, CA).
Flow Cytometric Analysis of T Lymphocytes in Lymph Nodes, Spleen, and Peripheral Blood of Transplant Recipients
At posttransplant days 7 and 25, mice were anesthetized with 2.5 mg of ketamine and 0.25 mg of xylazine and blood was collected by cardiac puncture and mixed with an equivalent volume of heparin in PBS (1000 U/mL; Sigma, St Louis, MO). The mice were then euthanized by cervical dislocation and their spleens and lymph nodes dispersed into single-cell suspensions by forcing the tissue through a 40-mM sterile nylon cell strainer. After red blood cell lysis, the cells were incubated for 20 minutes at 4°C with combinations of the following fluorochrome-conjugated antibodies: anti-CD4 (clone RM4-5), anti-CD8a (clone 53-6.7), anti-CD25 (clone PC61), anti-CD44 (clone IM7), and anti-CD45 (clone 30-F11), all from BD Pharmigen. All sample were fixed either in 0.4% paraformaldehyde in PBS (Sigma) for surface staining only or in eBioscience fixation/permeabilization buffer for combined cell surface and intracellular staining. Intracellular staining was carried out by washing fixed cells once in eBioscience permeabilization buffer and then incubating the cells with anti-FoxP3 conjugated to phycoerythrin in permeabilization buffer for 20 minutes. Flow cytometry was accomplished with a FAC-SAria machine, and data were analyzed with FlowJo software (Tree Star Inc, Ashland, OR).
Mixed Lymphocyte Reactions
Spleen cells from BALB/c transplant recipient mice were stained with violet proliferation dye (Invitrogen, Eugene, OR) as per the manufacturer's instructions. Splenocytes from C57BL/6 or BALB/c mice were exposed to 3000 rads of gamma radiation and used as stimulator cells. The labeled graft recipient splenocytes were then incubated in duplicate cultures with an equal number of C57BL/6 stimulator cells (experimental group), BALB/c stimulator cells (negative control), or BALB/c stimulator cells plus 0.1 mg/mL of anti-CD3 (clone 145-2C11; BD Pharmigen) as a positive control. After 3 days in culture, the supernatants and the cells were harvested. The cells were stained for surface markers as described previously, and cell viability was determined using FarRed viability (Invitrogen) stain to distinguish viable cells from dead cells via flow cytometry. Proliferation was measured by dye dilution using the FlowJo software.
The supernatants were analyzed by sandwich enzymelinked immunosorbent assay for interferon gamma (IFN-g). Briefly, Immulon 4HBX high-binding polystyrene enzymelinked immunosorbent assay plates (Thermo-Fisher, Rochester, NY) were coated with anti-IFN-g (clone R4-6A2) overnight at 4°C, washed with PBS plus 0.05% Tween 20 (Sigma), and the wells were blocked for 1 hour with PBS plus 0.05% Tween and 1% bovine serum albumin (Sigma). The wells were washed and then loaded with either 100 mL of diluted supernatant from the lymphocyte cultures or various concentrations of a purified mouse IFN-g standard. The plates were incubated overnight at 4°C, and the wells were washed and loaded with biotin-conjugated anti-IFN-g (clone XMG1.2; BD Pharmigen). After 1 hour at room temperature, the wells were washed, loaded with streptavidin conjugated to horseradish peroxidase, and incubated for 30 minutes at room temperature. The wells were washed and loaded with 100 mL of 3,39,5,59tetramethylbenzidine (TMB) peroxidase substrate (Fitzgerald Industries International, Acton, MA). Color development was stopped by the addition of 100 mL of 1N H 2 SO 4 , and absorbance was read at 450 nm using a SpectraMax plus plate reader (Molecular Devices).
Statistical Analysis
Corneal transplant survival in treated and untreated mice was plotted and significance determined by a log-rank test (GraphPad Software Inc, La Jolla, CA). The difference in the percent of clear or rejecting corneas at day 25 posttransplant was assessed using the x 2 test. All other values were compared by a student t test or a 1-way analysis of variance and Tukey post hoc test. The P values are noted in the figure legends when a significant difference was observed.
RESULTS
AZM Treatment Prolongs High-Risk Corneal Allograft Survival
The efficacy of AZM in prolonging high-risk corneal allograft survival was determined in fully major histocompatibility complex-mismatched (C57BL/6 to BALB/c) grafts. Recipients were either left untreated or treated daily with topical, oral, or both topical and oral AZM. Corneal allografts where scored as described in the Materials and Methods, and the graft was considered rejected upon 2 opacity scores of $3. AZM treatment by all 3 routes significantly reduced the rate and incidence of allograft rejection, and no significant FIGURE 1. AZM treatment significantly reduces the rejection rate of corneal allografts in high-risk BALB/c mice. BALB/c mice with suture-induced high-risk corneal beds received corneal grafts from major histocompatibility complex-mismatched C57BL/6 mice. The recipient mice were left untreated (; n = 11), received daily doses of 1% AZM solution directly on the eye (n; n = 14), received daily oral doses of 250 mg of AZM in PBS (:; n = 14), or received both topical and oral treatments daily ( ; ; n = 12). Rejection was based on 2 consecutive opacity scores of $3 as assessed by a masked observer. The differences in rejection rate between the control group and the AZM treatment groups were significant (P = 0.02) when assessed by a log-rank test. The incidence of rejection was significantly decreased in treated mice when compared with the control group (P , 0.05). No significant differences were observed among the treatment groups in rate or frequency of graft rejection.
differences were observed in graft survival among the AZM treatment groups (Fig. 1) .
Not all grafts developed corneal opacity and not all grafts that developed a corneal opacity rejected within 25 days of transplant. At day 25 posttransplant, the frequencies of clear corneal grafts (opacity score 0-0.5) among the treatment groups were as follows: 9% of controls, 33% of topical AZM treated, 43% of oral AZM treated, and 54% of topical plus oral AZM treated. The x 2 test revealed no significant differences among the treated groups but did reveal 
AZM Delays the Development of Opacity But Does Not Prevent Neovascularization in Corneal Allografts
Although some of the accepted corneal transplants remained clear through the 25-day observation period, others developed varying degrees of opacity. We observed a delay in the onset of opacity in mice that received topical AZM ( Fig. 2A) , resulting in a significant reduction in the area under the curve of the mean opacity scores (Fig. 2B) .
The reduced opacity scores in mice receiving topical AZM was not associated with a significant reduction in vascularization of the graft (Fig. 2C) . We did note a trend toward reduced vascularization in mice receiving combined oral and topical AZM treatment, but the difference did not achieve statistical significance at P , 0.05. These findings are in agreement with a previous study in which topical AzaSite reduced inflammation but failed to influence neovascularization in corneas with cautery-induced thermal injury. 24 
Treatment With AZM Changes the Inflammatory Infiltrate in Corneal Allografts
At 25 days posttransplant, corneas were harvested, fixed, and stained for CD45 and CD90 (a pan T-cell marker). The boundary between the grafted tissue and the recipient bed is visible in the brightfield images in the left-hand panels (Figs. 3A-D. We expected AZM treatment to prevent infiltration of immune effector cells into the graft. Interestingly, we observed a significantly larger leukocyte infiltrate in accepted corneas (though not in rejected corneas) of mice receiving only oral AZM (Figs. 3A, E-G) compared with mice that received topical and oral treatments (Figs. 3B, E-G). The reduced leukocytic infiltrate in topical + oral treatment group was observed in the corneal bed, graft interface, and within the allograft (Fig. 3 ).
AZM Does Not Significantly Alter the Regulatory T-Cell Population After Transplantation
Increased levels of FoxP3 expression in CD4 + T cells in the draining lymph node (DLN) positively correlate with corneal graft survival. 31 Therefore, we determined if AZM treatment influenced the frequency of FoxP3 + CD4 + regulatory T (T reg ) cells in the DLN of allograft recipients or their level of FoxP3 expression. Cells were obtained from the DLN 7 and 25 days after placement of corneal allografts and stained for CD4, CD44, and FoxP3. Flow cytometric analysis gating on CD4 + T cells revealed no significant differences in the frequency of T reg cells (CD4 + FoxP3 + ) in DLN of AZMtreated and control allograft recipients at 7 days posttransplant (data not shown) or 25 days posttransplant (Figs. 4A, B ). There were also no significant group differences in the relative mean fluorescence intensity (MFI) of FoxP3 expression ( Fig. 4C) . Surprisingly, we observed an increased ratio of CD4 effector cells (CD4 + CD44 high FoxP3 2 ) to T reg cells (CD4 + FoxP3 + ) in the AZM-treated groups, although the difference achieved statistical significance only in the topical AZM group (Fig. 4D ). 
AZM Treatment Does Not Alter T-Cell Function
We next determined if the reduced graft rejection in the AZM-treated mice correlated with a reduction in the relative size or functionality of CD4 + effector T cells in the spleen. Splenocytes were obtained from BALB/c graft recipients at 7 and 25 days after transplant of a C57BL/6 allogeneic cornea and stained for CD4, CD44, and FoxP3; and the frequency of CD4 + memory/effector T cells (CD + CD44 high FoxP3 2 ) was determined. A trend toward a lower frequency of CD4 + effector T cells was observed in AZM-treated groups at 7 days posttransplant (Fig. 5A ), but the differences did not achieve statistical significance. No group differences in frequency of CD4 + effector T cells was observed in spleens at 25 days posttransplant (Fig. 5B) . Splenocytes of BALB/c mice obtained 25 days after placement of corneal allografts were stained with violet proliferation dye and stimulated for 3 days with plate-bound anti-CD3, or with allogeneic (C57BL/6) or syngeneic (BALB/c) splenocytes. Splenocytes from BALB/c allograft recipient mice exhibited increased proliferation and IFN-g production in response to stimulation with allogeneic C57BL/6 stimulator cells relative to those stimulated with syngeneic BALB/c stimulator cells (data not shown). However, the levels of IFN-g production (Figs. 5C, D) and proliferation (Figs. 5E, F) were not significantly affected by any of the AZM treatment regimens.
DISCUSSION
We have demonstrated that AZM treatment significantly increases the number of grafts that survive a high-risk corneal transplant procedure. All the grafts included in this study had an intact anterior chamber, were not opaque during the first 5 days after surgery, and showed no other signs of surgical failure. Moreover, in our hands, syngeneic corneal grafts are not rejected, and allogeneic grafts are not rejected in CD4 T-cell-deficient mice (data not shown). Thus, our model is consistent with graft rejection and not graft failure. The administration of topical antibiotics is standard practice for corneal transplant recipients, and AzaSite is a broad-spectrum antibiotic that has been approved for use in treating ocular infections. Therefore, the addition of AzaSite to the posttransplant treatment regimen would benefit the patient through its dual antibacterial and antiinflammatory activity. Furthermore, our studies have demonstrated that the doses of AZM that effectively extend corneal graft acceptance do not have obvious side effects or cause a systemic reduction in measured immune functions. In our study, T cells in AZMtreated mice produced cytokines and proliferated as well as T cells in untreated mice when polyclonally stimulated with anti-CD3 directly ex vivo. Previous studies using higher doses of AZM did show broad effects on immune function, 18, 26, 27 but the clinically relevant doses employed in our studies effectively inhibited local inflammation without detectable systemic immune suppression.
The general antiinflammatory properties of the macrolide family have been studied primarily in models of chronic inflammatory airway diseases associated with bacterial infections. 25, 28, [32] [33] [34] [35] [36] In those studies, AZM was shown to inhibit both neutrophil and T-cell migration into inflamed airway tissue. Macrolides have varying effects on the production and efficacy of many proinflammatory cytokines such as IL-1, IL-6, IL-8 (CXCL8), and tumor necrosis factor, with AZM appearing to be the mildest antiinflammatory macrolide in the family. 18, 19 AZM treatment limits the signal strength of chemoattractants such as IL-8 and the production of inflammatory molecules such as granulocyte macrophage-colony stimulating factor that attract neutrophils to the sites of inflammation and are essential factors in graft rejection. 29, 30, 37, 38 Thus, AZM likely functions at least in part by inhibiting leukocytic infiltration into corneal allografts.
All 3 routes of AZM administration (topical corneal, oral, and combined) significantly reduced the incidence of graft rejection. However, the parameter defining rejection permits a significant amount of opacity to form in a nonrejected cornea. When the degree of opacity in rejected and nonrejected corneas was compared, 2 interesting observations emerged. First, at day 25 posttransplant, there was a higher frequency of clear corneas (opacity score of 0-0.5) in the treated groups compared with the untreated controls, although the difference was statistically significant only in the group receiving oral plus topical AZM. Thus, AZM not only reduced the frequency of rejection but also increased clarity in corneas that did not reject. The second observation was that topical AZM treatment reduced the opacity that typically occurs in the first few days after transplant. This finding is consistent with a previous study demonstrating that topical AZM inhibited an innate inflammatory response induced in the cornea by thermal cautery. 24 By reducing this early opacity, topical AzaSite might reduce or delay the activation of alloreactive CD4 + T cells and their infiltration into the corneal graft. A delay in the expansion of CD4 effector/memory cells would be consistent with our observations of a reduced T effector/memory population at day 7 posttransplant ( Fig. 5 ) but enlarged population at day 25 (Fig. 4) .
The AZM treatment groups also differed with respect to the magnitude of the corneal infiltrate. The corneas treated with topical AZM showed a reduction in the relative T-cell infiltrate compared with mice treated with oral AZM (Fig. 3) . The overall CD45 infiltrate in accepted grafts was also reduced in the allograft recipients that were treated with topical AZM when compared with the oral AZM-treated mice. This is consistent with previous studies demonstrating that AZM can reduce the chemokines, cytokines, and adhesion molecules required for leukocytic extravasation from blood. 25, 38 These findings suggest that topical AZM is more effective than oral AZM at inhibiting leukocyte extravasation into grafted corneas and that the size of the leukocytic infiltrate can vary significantly in corneas with similar opacity scores. Despite the reduced incidence of corneal graft rejection in AZM-treated mice, vascularization of the allograft was not significantly reduced. A previous study demonstrated that topical corneal AZM treatment failed to inhibit vascularization after implantation of vascular endothelial growth factor-A-containing pellets in the cornea. 24 Together with our findings, this suggests that AZM is ineffective at blocking corneal vascularization but does appear to inhibit leukocytic extravasation from corneal vessels.
Although not exhaustive, our studies did not demonstrate an effect of AZM on the generation or function of alloreactive CD4 + T cells, or on the generation of T reg cells. There was no difference in the frequency of CD4 + CD44 high FoxP3 2 effector/memory T cells in the spleens of AZMtreated or nontreated allograft recipients at 7 or 25 days postgrafting. In fact, the AZM-treated mice tended to have a higher ratio of CD4 + effector T cells to T reg cells than the nontreated controls. There was no significant difference in the ability of spleen cells from AZM-treated allograft recipients to produce IFN-g or proliferate in response to alloantigens. Therefore, it does not appear that AZM treatment markedly affected the generation or function of allospecific CD4 + T cells, although a more comprehensive study including earlier time points after corneal transplantation will be required to firmly establish this point.
The finding that topical AZM treatment is highly effective in reducing the incidence of corneal graft rejection in a high-risk mouse model is very encouraging. Because the 1% ophthalmic AZM solution AzaSite is now Food and Drug Administration approved for treatment of bacterial or trachomatous conjunctivitis, and administration of topical antibiotics is standard practice for all corneal transplant recipients, it would seem reasonable to extend these studies to humans who are at high risk for corneal graft rejection because of previous inflammatory corneal conditions.
